Summary of the Third Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Minimal residual disease (MRD) assessment increasingly is reported along with traditional response rates as part of the outcomes of clinical trials as well as being incorporated into clinical trial design. Consensus criteria for MRD assessment and MRD response have been established by the International Myeloma Working Group (IMWG). [1] Currently there are two sanctioned methodologies: multiparametric flow cytometry (MFC) and next generation sequencing (NGS). [1] More specifically, MFC is to be performed using the established Euro-Flow procedure which involves an eight-color, two-tube method and has a minimum sensitivity of 1  × 10−5.

Source: Biology of Blood and Marrow Transplantation - September 13, 2019 Category: Hematology Authors: Sarah A. Holstein, Zaid Al-Kadhimi, Luciano J. Costa, Theresa Hahn, Parameswaran Hari, Jens Hillengass, Allison Jacob, Nikhil C. Munshi, Stefania Oliva, Marcelo C. Pasquini, Qian Shi, Edward A. Stadtmauer, Stephanie L. Waldvogel, Philip L. McCarthy Source Type: research